France's Sanofi-Aventis is spending €350 million to build a site to produce a potential blockbuster dengue vaccine that is still in development. The high-technology site should be up and running in 2013 to produce 100 million doses of the dengue vaccine which should become available in 2014 in the endemic regions such as Asia Pacific. The new plant will be located in Neuville-sur-Saone, near Sanofi Pasteur's headquarters in Lyon, France. Sanofi has 12 manufacturing sites under construction or undergoing major renovation and they will come on line in 2009. Among them is the recently approved U.S. factory in Pennsylvania, which is to produce the seasonal flu vaccine Fluzone.